MedTrace Logo

Cognitive Behavioral Therapy in Prolonging the Antidepressant Effects of Intravenous Ketamine

NCT02289248 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2017-03-01

No results posted yet for this study

Summary

Subjects with depressive episodes will be recruited to undergo a brief 2 week course of IV infusions of ketamine in combination with cognitive behavioral therapy for 8 weeks.

Conditions

Interventions

DRUG

Ketamine

Subjects will undergo a twice weekly two week course of IV infusions of ketamine

BEHAVIORAL

Cognitive Behavioral Therapy (CBT)

Subjects will undergo twice weekly CBT for a total of 8 weeks

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Samuel Wilkinson, MD · Yale University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-28
Primary Completion
2016-10-31
Completion
2016-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02289248 on ClinicalTrials.gov